Solid Tumor Targeted Cancer Gene Panel by Next Generation Sequencing
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Targeted cancer therapies are defined as antibody or small molecule drugs that block the growth and spread of cancer by interfering with specific cell molecules involved in tumor growth and progression. Multiple targeted therapies have been approved by the United States Food and Drug Administration (FDA) for treatment of specific cancers. Molecular genetic profiling is often needed to identify targets amenable to targeted therapies and to minimize treatment costs and therapy-associated risks.
Next generation sequencing has recently emerged as an accurate, cost-effective method to identify mutations across numerous genes known to be associated with response or resistance to specific targeted therapies. CANCP / Solid Tumor Targeted Cancer Gene Panel by Next Generation Sequencing is a single assay that uses formalin-fixed paraffin-embedded tissue to assess for common mutations in 50 genes known to be associated with cancer. The results of this test can be useful for assessing prognosis and guiding treatment of individuals with solid tumors. These data can also be used to help determine clinical trial eligibility for patients with mutations in genes not amenable to current FDA-approved targeted therapies.
See Targeted Gene Regions Interrogated by Solid Tumor Targeted Cancer Gene Panel by Next Generation Sequencing in Special Instructions for details regarding the targeted gene regions identified by this test.
Identifying tumors that may respond to targeted therapies by assessing multiple gene targets simultaneously
Identifying specific mutations within genes known to be associated with response or resistance to specific cancer therapies
Identifying mutations that may help determine prognosis for patients with solid tumors
Assisting in establishing a diagnosis (eg, KIT and PDGFRA alterations for gastrointestinal stromal tumors)
An interpretive report will be provided.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
This test cannot differentiate between somatic and germline alterations. Additional testing may be necessary to clarify the significance of results if there is a potential hereditary risk.
DNA variants of uncertain significance may be identified.
A negative (wild-type) result does not rule out the presence of a mutation that may be present but below the limits of detection of this assay (approximately 5%-10%).
This test does not detect large single or multi-exon deletions or duplications or genomic copy number variants.
Rare polymorphisms may be present that could lead to false-negative or false-positive results. Test results should be interpreted in the context of clinical findings, tumor sampling and other laboratory data. If results obtained do not match other clinical or laboratory findings, please contact the laboratory for updated interpretation. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
An interpretive report will be provided.
Clinical References Provides recommendations for further in-depth reading of a clinical nature
1. Targeted Cancer Therapies. National Cancer Institute Fact Sheet. Updated 12/05/2012. Available at URL: http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted. Accessed December 2013
2. Vogelstein B, Papadopoulos N, Velculescu VE, et al: Cancer genome landscapes. Science 2013;339:1546-1558
3. Beadling C, Neff TL, Heinrich MC, et al: Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. J Mol Diagn 2013;15:171-176